


SITERA Biotech Executive Summary

Targeting the **Mitochondria-Associated Membranes (MAM)** : a key hub in cell metabolism



MAM **Dysfunction** in
Neurodegenerative diseases

**Elevated ROS
production**

Mitophagy

MAM **Targeting** :
Targeted therapies
Mitochondrial health
Neuroplasticity

SITERA operates a **unique, cutting-edge** technological platform in **neurosciences**, designed to :

Generate potential *first or best-in-class* candidates

Address MAM dysfunctions and restore cellular impairments

Provide therapeutic solutions for **neurodegenerative diseases**

1



Focus on rare and less rare neurodegenerative diseases : Wolfram syndrome, Charcot-Marie Tooth 2A, ALS but also Alzheimer's and Parkinson's disease. **Total market size** : 65G\$ by 2030

2



Strong and large IP portfolio encompassing 2 patents (2021 on the target, 2025 - Composition of matter), a pipeline of +300 New Chemical Entities distributed in 3 chemical series

3



PoC with Wolfram syndrome and rapid extension to other diseases
This strategy is supported by common target&MOA and conclusive *in vivo* Proof-Of-Concept on preclinical animal models

4



Orphan Drug/Fast Track Designation

Our drug candidate SIT3060 addresses an unmet medical need as there is no treatment available to treat Wolfram Syndrome

5



Financials: Looking for 15 M€ to complete regulatory preclinical up to clinical Proof-Of-Concept for SIT3060, our drug candidate in Wolfram syndrome